Skip to main content

NCBiotech News

  • Genetron Health Co. Ltd., a Chinese precision-medicine company with a presence in North Carolina and ties to Duke University, has been listed among China’s top 50 companies with the most investment value.
  • “Better than flax. Not from fish.” That’s the simple value proposition for a new plant-based oil rich in nutritional omega fatty acids being launched by Technology Crops International (TCI) of Winston-Salem.
  • Dignify Therapeutics, a drug-development company focused on restoring bladder and bowel control to people with spinal injury, spina bifida, and other neurological conditions, has received $3.1 million in federal funding to advance its lead drug candidate.
  • Global Agribusiness Executive Sees Opportunity for North Carolina
  • Expert says many biotech companies may be trying to create consumer acceptance and trust for products such as genetically modified organisms (GMOs) and other new technologies the wrong way.
  • The North Carolina Biotechnology Center awarded 17 grants and loans totaling $1,060,352 to companies, universities and nonprofit organizations across the state during the first quarter of its 2016-2017 fiscal year ending September 30.
  • Despite some consumer resistance to genetic engineering, not all food technology innovations discussed at the North Carolina Biotechnology Center’s AgBiotech Summit 2016 engender social fears.
  • When technology impacts the food chain, sometimes the food chain bites back. Those kinds of lessons were the theme for the second day of the recent two-day North Carolina Biotechnology Center AgBio Summit in Chapel Hill.
  • The North Carolina Biotechnology Center, aided by a $1.87 million federal grant, has embarked on a three-year project to study the production of sorghum as biomass for fuel and high-value chemicals in the Mid-Atlantic region.
  • Some of the many partners who teamed up to recruit a $1 billion cell culture flu vaccine factory to Holly Springs, N.C., got a tangible reminder of the fruits of their 13-year labor on Tuesday as they rolled up their sleeves for a shot of the game-changing vaccine made by fellow North Carolinians.
  • Four leaders in the field examined the potential for milk and meat without cows, and eggs without hens, as part of the North Carolina Biotechnology Center’s AgBiotech Summit 2016 in Chapel Hill.
  • “This is the best time ever to be alive and to be in agriculture,” Lowell Catlett, Ph.D, an economist and futurist, told the lunch session at the North Carolina Biotechnology Center’s AgBiotech Summit 2016.
  • BioMedomics, a medical diagnostics company in Research Triangle Park, won first place among 30 start-up companies competing in an innovation contest at an industry conference in Boston.
  • Almac Group, a global contract research organization (CRO) with 288 employees in Durham, has announced a $5.2 million expansion that will create 79 more jobs over the next three years.
  • Flucelvax Quadrivalent: A Next-Generation Flu Vaccine Flucelvax Quadrivalent is an influenza vaccine developed and produced by Seqirus.
  • Now is the best time to sign up for your flu shot, and this is the best place to do it. When you reserve a 10-minute “NC Big Shot" slot on the North Carolina Biotechnology Center’s website for the Tuesday, October 4 VaccinatioNCelebration, it’ll reserve your free ticket to participate in a milestone of medicine.
  • Raleigh-based PRA Health Sciences (PRA) and Takeda Pharmaceutical Co. of Japan have formed a partnership in which PRA will serve as Takeda’s primary strategic partner for clinical development and post-approval work on Takeda’s drug pipeline and marketed products.
  • Charlotte-area biopharmaceutical company SoyMeds has been awarded a $1.05 million two-year grant from the National Institutes of Health to help advance its unique system for “growing” a medicine in transgenic soybeans.
  • Kepley BioSystems, a startup company in Greensboro, has developed OrganoBait, an artificial attractant for commercial and recreational crabbers and lobstermen.
  • BioCryst Pharmaceuticals of Durham has reported positive results from a proof-of-concept study of its broad-spectrum antiviral BCX4430 for the delayed treatment of Ebola virus infection in rhesus macaques.


Subscribe to News & Events